Orchestra BioMed (OBIO) director trust buys 20,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Orchestra BioMed Holdings director Eric S. Fain, through the Fain Living Trust, bought 20,000 shares of common stock in an open-market purchase on May 14, 2026 at a weighted average price of $4.13 per share. Following this transaction, the trust holds 91,709 shares indirectly.

Insider Trade Summary

Net Buyer: 20,000 shares ($82,600)

Net Buy 1 txn

Insider Fain Eric S

Role null

Bought 20,000 shs ($83K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share	20,000	$4.13	$83K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 91,709 shares (Indirect, By the Fain Living Trust)

Footnotes (1)

[object Object]

Key Figures

Shares purchased: 20,000 shares Weighted average price: $4.13 per share Shares held after transaction: 91,709 shares +1 more

4 metrics

Shares purchased 20,000 shares Open-market buy on May 14, 2026

Weighted average price $4.13 per share Open-market purchase range $4.10–$4.14

Shares held after transaction 91,709 shares Indirect holdings via the Fain Living Trust

Net buy shares 20,000 shares Net-buy direction in transaction summary

Key Terms

open-market purchase, indirect ownership, weighted average price, Form 4

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"ownership_type: "indirect" and nature_of_ownership: "By the Fain Living Trust""

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 08:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fain Eric S

(Last)

(First)

(Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE

PENNSYLVANIA

18938

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.0001 per share	05/14/2026		P		20,000	A	$4.13⁽¹⁾	91,709	I	By the Fain Living Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.14. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Andrew Taylor, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Orchestra BioMed (OBIO) director Eric S. Fain report in this Form 4?

Director Eric S. Fain reported an indirect open-market purchase of Orchestra BioMed common stock. The Fain Living Trust acquired 20,000 shares, and this filing updates his indirect ownership position as required for insiders under U.S. securities regulations.

How many Orchestra BioMed (OBIO) shares were bought in the reported transaction?

The filing shows a purchase of 20,000 shares of Orchestra BioMed common stock. These shares were acquired in an open-market transaction and increase the number of shares held indirectly through the Fain Living Trust to a total of 91,709 shares.

At what price did the Fain Living Trust buy OBIO shares in this Form 4?

The shares were purchased at a weighted average price of $4.13 per share. The footnote explains that individual trades occurred between $4.10 and $4.14, and detailed trade-by-trade pricing is available upon request from the parties listed.

Is Eric S. Fain’s ownership in Orchestra BioMed direct or indirect?

The reported ownership in this Form 4 is indirect, held through the Fain Living Trust. The filing classifies the holdings with an indirect ownership code, indicating the trust is the legal holder of the Orchestra BioMed common stock rather than Fain personally.

How many Orchestra BioMed (OBIO) shares does the Fain Living Trust hold after this transaction?

After the reported purchase, the Fain Living Trust holds 91,709 shares of Orchestra BioMed common stock. This figure reflects the updated indirect ownership position following the 20,000-share open-market acquisition reported in the Form 4 filing.

What does the weighted average price disclosure mean in this Orchestra BioMed Form 4?

The weighted average price of $4.13 per share reflects multiple trades executed between $4.10 and $4.14. The footnote notes that detailed information on the number of shares at each separate price will be provided upon request to specified interested parties.